Category: Latest News
-
Victory Marine Holdings Appoints E-Commerce Director to Scale GUTSI Omnichannel Growth
Victory Marine Holdings has appointed Miles Bodie as Director of E-Commerce at its Dunn & Groux Beverage Holdings subsidiary, adding dedicated leadership to expand GUTSI across Amazon, Walmart Marketplace and direct-to-consumer channels. Key Investor Takeaways Why VMHG Stock Is in Focus Victory Marine’s DGBH subsidiary has appointed Bodie to lead the next phase of its…
-
Netlist Files Patent Infringement Action Against Micron at U.S. International Trade Commission
Netlist has launched new patent infringement proceedings against Micron and other technology companies at the U.S. International Trade Commission, seeking orders that could block allegedly infringing memory products from entering the United States. The company has also filed a separate patent lawsuit against Micron in federal court in California. Key Investor Takeaways Why (USOTC:NLST) Stock…
-
BioAdaptives Launches XcellaraHeart With Pre-Orders Ahead of August 26 Shipments
BioAdaptives has commercially launched XcellaraHeart, opening pre-orders for the flagship product in its seven-formula Xcellara cellular wellness platform, with the first commercial batch scheduled to ship on August 26, 2026. Key Investor Takeaways Why BDPT Stock Is in Focus BioAdaptives has officially launched XcellaraHeart, shifting its Xcellara cellular wellness strategy into the commercial stage. Limited…
-
Cardiff Lexington H1 Revenue Declines as Working Capital Constraints Pressure Performance
Cardiff Lexington reported lower year-to-date revenue and a near-breakeven adjusted EBITDA result for the first half of 2026, as weaker realization rates on patient case settlements and working capital constraints offset growth in new patients and surgical procedures. Key Investor Takeaways Why CDIX Stock Is in Focus Cardiff Lexington’s second-quarter filing highlights a divergence between…
-
Valion Bio Advances Government-Funded Entolimod Radiation Injury Studies With Data Expected in Early Fall
Valion Bio is moving into a near-term government-funded Entolimod study programme evaluating protection against lethal radiation-induced gastrointestinal injury, with safety dosing planned to begin this week and top-line therapeutic data anticipated in early fall. Key Investor Takeaways Why VBIO Stock Is in Focus Valion Bio’s Entolimod programme is approaching an important experimental stage as AFRRI…
-
Capstone Q2 Revenue Jumps 67% as Stone Business Adjusted EBITDA Turns Positive
Capstone Holding reported 67% year-over-year revenue growth in the second quarter of 2026, while Stone Business Adjusted EBITDA reached $2.0 million and turned positive sequentially as previously guided. The building products distributor also reaffirmed its full-year 2026 financial guidance. Key Investor Takeaways Why (NASDAQ:CAPS) Stock Is in Focus Capstone’s second-quarter results showed faster gross profit…
-
Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months as NB1 Study Advances
Bone Biologics has extended the validated shelf life of its rhNELL-1 protein to 32 months, giving the company greater manufacturing and supply-chain flexibility as it prepares for larger-scale clinical development and advances enrollment in its first-in-human NB1 study. Key Investor Takeaways Why (NASDAQ:BBLG) Stock Is in Focus Bone Biologics has validated a 32-month shelf life…
-
Zhibao Technology Forms AI-Native Long-Term Insurance Joint Venture With Dongbaohui
Zhibao Technology has signed an agreement with Dongbaohui to establish a joint venture focused on AI-native embedded long-term insurance, adding a new strategic growth initiative alongside its existing 2B2C digital insurance business. Key Investor Takeaways Why ZBAO Stock Is in Focus Zhibao Technology is expanding its business model into long-term insurance through a newly agreed…
-
SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product
SCIENTURE has commercially launched REZENOPY, its 10 mg naloxone nasal spray, and fulfilled initial purchase orders to U.S. pharmaceutical wholesalers, moving its second FDA-approved commercial product into nationwide distribution. Key Investor Takeaways Why SCNX Stock Is in Focus SCIENTURE has fulfilled its first REZENOPY purchase orders to U.S. pharmaceutical wholesalers and commenced nationwide distribution, marking…
-
Intuit Expands Conversational AI Across Mid-Market Finance Platform
Intuit is rolling out Intuit Intelligence Chat and broader AI-powered financial capabilities across QuickBooks Online Advanced and Intuit Enterprise Suite, strengthening its push into more complex mid-market finance workflows. Key Investor Takeaways Why INTU Stock Is in Focus Intuit is expanding Intuit Intelligence across QuickBooks Online Advanced and Intuit Enterprise Suite, with Intuit Intelligence Chat…